EYPT - EyePoint Pharmaceuticals, Inc.
NASDAQ
->
Healthcare
->
Biotechnology
Watertown,
United States
Type: Equity
EYPT price evolution
EYPT
| (in millions $) | 31 Dec 2023 | 30 Sep 2023 | 30 Jul 2023 | 31 Mar 2023 |
|---|---|---|---|---|
| Current assets | ||||
| Cash | $281.41 | $133.19 | $139.75 | $105.92 |
| Short term investments | $49.79 | $2.98 | $2.94 | $16.72 |
| Net receivables | $0.81 | $0.48 | $10.95 | $10.42 |
| Inventory | $3.91 | $4.58 | $4.26 | $4.07 |
| Total current assets | $344.8 | $150.16 | $167.12 | $146.06 |
| Long term investments | ||||
| Property, plant & equipment | $10.23 | $9.73 | $8.39 | $8.39 |
| Goodwill & intangible assets | ||||
| Total noncurrent assets | $10.38 | $9.88 | $8.54 | $8.54 |
| Total investments | $49.79 | $2.98 | $2.94 | $16.72 |
| Total assets | $355.18 | $160.04 | $175.66 | $154.59 |
| Current liabilities | ||||
| Accounts payable | $6.5 | $9.58 | $10.72 | $9.45 |
| Deferred revenue | $59.28 | $72.18 | $86.11 | $14.51 |
| Short long term debt | $5.29 | |||
| Total current liabilities | $63.26 | $63.9 | $68.92 | $27.24 |
| Long term debt | $4.91 | $5.18 | $5.46 | $35.09 |
| Total noncurrent liabilities | $25.6 | $37.53 | $49.48 | $48.96 |
| Total debt | $4.91 | $5.18 | $5.46 | $40.39 |
| Total liabilities | $88.86 | $101.42 | $118.39 | $76.2 |
| Shareholders' equity | ||||
| Retained earnings | -$742.15 | -$728.05 | -$715.43 | -$692.51 |
| Other shareholder equity | $0.86 | $0.84 | $0.84 | $0.84 |
| Total shareholder equity | $266.32 | $58.62 | $57.26 | $78.39 |
| (in millions $) | 31 Dec 2023 | 31 Jan 2023 | 31 Dec 2021 | 31 Dec 2020 |
|---|---|---|---|---|
| Current assets | ||||
| Cash | $281.41 | $95.78 | $178.74 | $45.06 |
| Short term investments | $49.79 | $48.93 | $32.97 | |
| Net receivables | $0.81 | $15.5 | $18.35 | $9.45 |
| Inventory | $3.91 | $2.89 | $3.62 | $5.34 |
| Total current assets | $344.8 | $172.81 | $237.75 | $63.12 |
| Long term investments | ||||
| Property, plant & equipment | $10.23 | $7.4 | $2.73 | $3.24 |
| Goodwill & intangible assets | $22.75 | $25.21 | ||
| Total noncurrent assets | $10.38 | $7.55 | $25.63 | $28.6 |
| Total investments | $49.79 | $48.93 | $32.97 | |
| Total assets | $355.18 | $180.36 | $263.37 | $91.72 |
| Current liabilities | ||||
| Accounts payable | $6.5 | $5.92 | $7.38 | $4.81 |
| Deferred revenue | $59.28 | $14.76 | $15.63 | $16.56 |
| Short long term debt | $10.47 | |||
| Total current liabilities | $63.26 | $34.54 | $23.66 | $14.89 |
| Long term debt | $4.91 | $29.31 | $38.42 | $40.31 |
| Total noncurrent liabilities | $25.6 | $49.45 | $55.33 | $58.29 |
| Total debt | $4.91 | $45.77 | $38.42 | $40.31 |
| Total liabilities | $88.86 | $83.99 | $78.99 | $73.18 |
| Shareholders' equity | ||||
| Retained earnings | -$742.15 | -$671.35 | -$569.1 | -$510.68 |
| Other shareholder equity | $0.86 | $0.79 | $0.84 | $0.84 |
| Total shareholder equity | $266.32 | $96.37 | $184.38 | $18.54 |
| (in millions $) | 31 Dec 2023 | 30 Sep 2023 | 30 Jul 2023 | 31 Mar 2023 |
|---|---|---|---|---|
| Revenue | ||||
| Total revenue | $14.03 | $15.2 | $7.68 | |
| Cost of revenue | $1 | $1.2 | $0.64 | |
| Gross Profit | $13.03 | $14 | $7.04 | |
| Operating activities | ||||
| Research & development | $17.95 | $17.36 | $13.62 | |
| Selling, general & administrative | $11.43 | $11.04 | $14.98 | |
| Total operating expenses | $29.38 | $28.4 | $28.6 | |
| Operating income | -$16.35 | -$14.4 | -$21.55 | |
| Income from continuing operations | ||||
| EBIT | -$14.02 | -$12.61 | -$20.35 | |
| Income tax expense | $0.08 | |||
| Interest expense | $0.81 | |||
| Net income | ||||
| Net income | -$14.1 | -$12.61 | -$21.16 | |
| Income (for common shares) | -$14.1 | -$12.61 | -$21.16 | |
| (in millions $) | 31 Dec 2023 | 31 Dec 2022 | 31 Jan 2022 | 31 Dec 2020 |
|---|---|---|---|---|
| Revenue | ||||
| Total revenue | $46.02 | $41.4 | $34.44 | |
| Cost of revenue | $4.63 | $8.33 | $5.82 | |
| Gross Profit | $41.39 | $33.08 | $28.61 | |
| Operating activities | ||||
| Research & development | $64.66 | $49.64 | $17.42 | |
| Selling, general & administrative | $51.79 | $60.32 | $46.02 | |
| Total operating expenses | $116.45 | $132.72 | $65.9 | |
| Operating income | -$75.07 | -$99.64 | -$37.29 | |
| Income from continuing operations | ||||
| EBIT | -$69.47 | -$99.06 | -$38.14 | |
| Income tax expense | $0.08 | |||
| Interest expense | $1.25 | $3.19 | $7.26 | |
| Net income | ||||
| Net income | -$70.8 | -$102.25 | -$45.39 | |
| Income (for common shares) | -$70.8 | -$102.25 | -$45.39 | |
| (in millions $) | 31 Dec 2023 | 30 Sep 2023 | 30 Jun 2023 | 31 Mar 2023 |
|---|---|---|---|---|
| Net income | -$14.1 | -$12.61 | -$22.92 | -$21.16 |
| Operating activities | ||||
| Depreciation | $0.11 | $0.12 | $0.13 | $0.1 |
| Business acquisitions & disposals | ||||
| Stock-based compensation | $3.59 | $3.63 | $1.79 | $3.05 |
| Total cash flows from operations | -$23.11 | -$15.2 | $57.02 | -$16.84 |
| Investing activities | ||||
| Capital expenditures | -$0.88 | -$1.72 | -$0.4 | -$0.48 |
| Investments | -$46.27 | $13.86 | $32.57 | |
| Total cash flows from investing | -$47.15 | -$1.72 | $13.47 | $32.09 |
| Financing activities | ||||
| Dividends paid | ||||
| Sale and purchase of stock | $218.52 | $10.78 | $0.01 | $0.25 |
| Net borrowings | -$36.66 | -$5.2 | ||
| Total cash flows from financing | $218.49 | $10.36 | -$36.66 | -$5.12 |
| Effect of exchange rate | ||||
| Change in cash and equivalents | $148.23 | -$6.56 | $33.83 | $10.13 |
| (in millions $) | 31 Dec 2023 | 31 Dec 2022 | 31 Dec 2021 | 31 Dec 2020 |
|---|---|---|---|---|
| Net income | -$70.8 | -$102.25 | -$58.42 | -$45.39 |
| Operating activities | ||||
| Depreciation | $0.46 | $2.45 | $2.77 | $2.65 |
| Business acquisitions & disposals | ||||
| Stock-based compensation | $12.06 | $14.18 | $7.45 | $5.55 |
| Total cash flows from operations | $1.88 | -$65 | -$50.1 | -$14.44 |
| Investing activities | ||||
| Capital expenditures | -$3.48 | -$2.15 | -$0.16 | -$0.36 |
| Investments | $0.17 | -$15.12 | -$32.97 | |
| Total cash flows from investing | -$3.31 | -$17.27 | -$33.12 | -$0.36 |
| Financing activities | ||||
| Dividends paid | ||||
| Sale and purchase of stock | $229.55 | $0.4 | $217.2 | $50.21 |
| Net borrowings | -$41.86 | -$0.19 | -$0.15 | -$12.63 |
| Total cash flows from financing | $187.07 | -$0.69 | $216.9 | $37.49 |
| Effect of exchange rate | ||||
| Change in cash and equivalents | $185.63 | -$82.96 | $133.68 | $22.7 |
News
Fundamentals
| Market cap | $804.38M |
|---|---|
| Enterprise value | $527.87M |
| Shares outstanding | 48.84M |
| Revenue | N/A |
|---|---|
| EBITDA | N/A |
| EBIT | N/A |
| Net Income | N/A |
| Revenue Q/Q | 33.18% |
| Revenue Y/Y | N/A |
| P/E ratio | N/A |
|---|---|
| EV/Sales | N/A |
| EV/EBITDA | N/A |
| EV/EBIT | N/A |
| P/S ratio | N/A |
| P/B ratio | 3.03 |
| Book/Share | 5.44 |
| Cash/Share | 5.76 |
| EPS | N/A |
|---|---|
| ROA | N/A |
| ROE | N/A |
| Debt/Equity | 0.33 |
|---|---|
| Net debt/EBITDA | N/A |
| Current ratio | 5.45 |
| Quick ratio | 5.39 |